Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 13a. Predictors of Disease Response or Survival—Clinical Diagnostic Tests That Predict Response to Thalidomide: Summary

Prognostic Factor

Number of studies indicating significant correlation with tumor response/ total number of studies indicating factor

Number of studies indicating significant correlation with survival/ total number of studies indicating factor

Cytogenetics

Correlation with response=2/2
(Barlogie, 200143; Shaughnessy, 2003133)

Correlation with survival=1/1
(Shaughnessy, 2003133)

Chromosome 13 abnormality

Correlation with response=2/3
(Barlogie, 2002109; Shaughnessy, 2003133)

No correlation=1/3
(*Attal, 2004 (ASH 535)108)

Correlation with survival=4/4
(Barlogie, 2002109; Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133; Singhal, 199935)

Albumin

Some correlation with response=2/3
(Dimopoulos, 200494; Yakoub-Agha, 200260)

No correlation=1/3
(Shaughnessy, 2003133)

Correlation with survival=3/3
(Shaughnessy, 2003133; Singhal, 199935; Yakoub-Agha, 200260)

Beta 2 microglobulin (B2M)

Some correlation with response=4/5
(Garcia-Sanz, 200495; Shaughnessy, 2003133; Schutt, 200587; *Attal, 2004 (ASH 535)108)

No correlation=1/5
(Neben, Moehler, Egerer, et al., 200152

Correlation with survival=3/3
(Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133; Schutt, 200587)

Hemoglobin

No correlation=1/1
(Neben, Moehler, Egerer, et al., 200152)

No correlation=2/2
(Dimopoulos, 200170; Mileshkin, Biagi, et al., 200399)

Platelets

Correlation with response=1/1
(Garcia-Sanz, 200495)

 

Serum lactose dehydrogenase (LDH)

Correlation with response=3/3
(Dimopoulos, 200494; Shaughnessy, 2003133; Singhal, 199935)

Correlation with survival=4/4
(Dimopoulos, 200170; Dimopoulos, 200494; Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133)

C Reactive Protein (CRP)

Correlation with response=2/2
(Shaughnessy, 2003133; Singhal, 199935)

Correlation with survival=1/1
(Shaughnessy, 2003133)

IgA isotype

Correlation with response=1/1
(Yakoub-Agha, 200260)

Correlation with survival=1/1
(Yakoub-Agha, 200260)

Light chain type

Correlation with response=1/1
(Dimopoulos, 200170)

Correlation with survival=1/1
(Dimopoulos, 200170)

Plasma cell labeling index (PCLI)

Correlation with response=2/2
(Barlogie, 200143; Singhal, 199935)

 

Abbreviations: *=abstract, BM=bone marrow, B2M=beta-2 microglobulin, FGF=Fibroblast Growth Factor, CRP=C-reactive protein, CT=chemotherapy, CTD=cyclophosphamide + Thalidomide + Dexamethasone, d=day, Dex=Dexamethasone, dL=deciliter, EFS=event free survival, FISH=fluorescence in situ hybridization, f/u=followup, g=grams, HDCT=high dose chemotherapy, HR=hazard ratio, IFN=interferon, IU=international units, L=liter, LDH=?, med=median, mo=month, ml=milliliter, NS=not stated, OS=overall survival, PCLI=plasma cell labeling index, PPR=paraprotein reduction, pt(s)=patient(s), RCT=randomized controlled trial, RR=relative risk, SCT=stem cell transplant, Thal=Thalidomide, tx'd=treated, ULN=upper limit of normal, VEGF=Vascular endothelial growth factor, vs.=versus, w/=with, yr=year

Return to Document
Proceed to Table 13b

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care